Source: Annual Congress 2008 - Deadly networks: disease-causing protein and DNA modifications



Rating:

Share or cite this content

Citations should be made in the following way:
P. J. Barnes (London, United Kingdom). Clinical implications and opportunities for new drug therapies. Annual Congress 2008 - Deadly networks: disease-causing protein and DNA modifications

Member's Comments

No comment yet.

Related content which might interest you: Clinical implications and novel therapies Source: International Congress 2018 – Accelerated ageing in lungs Year: 2018 COPD mechanisms: novel aspects and implications for new therapies Source: ERS Live 2007 Year: 2007 Clinical implications – potential future developments in EBC research Source: Annual Congress 2007 - ERS/ATS joint symposium: the report of the ERS/ATS Task Force on Exhaled Breath Condensate Year: 2007 Recommendations of new therapies for severe asthma and the future Source: Annual Congress 2013 –ERS/ATS Task Force report on severe asthma Year: 2013 Facts and perspectives in the development of new anti-TB drugs Source: Annual Congress 2008 - New insights into tuberculosis control Year: 2008 Pathophysiology and potential future therapeutic targets using preclinical models of COVID-19 Source: ERJ Open Res, 6 (4) 00405-2020; 10.1183/23120541.00405-2020 Year: 2020 Clinical use of new and repurposed drugs: the role and contribution of the ERS collaborative projects Source: International Congress 2017 – In the frontline of the fight against tuberculosis Year: 2017 Evidence-based medicines for children: important implications for new therapies at all ages Source: Eur Respir J 2006; 28: 1069-1072 Year: 2006 Therapeutic management - Current status and future developments Source: COVID-19 Videos Year: 2020 Clinical implications of the new concepts regarding COPD pathophysiology Source: Annual Congress 2008 - New insights into COPD pathophysiology Year: 2008 Biologics: current use and future applications for personalised therapy Source: Virtual Congress 2021 – Wheezing illnesses along the life span Year: 2021 Characterisation of clinical phenotypes is mandatory for the development of new drugs Source: Research Seminar 2014 - Human translational medicine: a key bridge for the development of new drugs for severe asthma, COPD and ILD Year: 2014 COVID-19 conundrum: clinical phenotyping based on pathophysiology as a promising approach to guide therapy in a novel illness Source: Eur Respir J, 56 (2) 2002135; 10.1183/13993003.02135-2020 Year: 2020 Current and future preventive and treatment strategies in CLAD Source: International Congress 2015 – When chronic inflammation drives fibrosis: a lesson from lung transplantation Year: 2015 Therapeutic implications Source: Annual Congress 2009 - The lung cancer-COPD nexus Year: 2009 Therapeutic drug monitoring practice in patients with active tuberculosis: assessment of opportunities Source: Eur Respir J, 57 (1) 2002349; 10.1183/13993003.02349-2020 Year: 2021 Facts and perspectives in the development of new diagnostics Source: Annual Congress 2008 - New insights into tuberculosis control Year: 2008